New hope for pancreatic cancer: experimental drug combo enters large trial
NCT ID NCT07490301
First seen Mar 26, 2026 · Last updated Jun 19, 2026 · Updated 17 times
Summary
This study tests a new drug called telisotuzumab adizutecan combined with standard chemotherapy (FOLFOX) for people with metastatic pancreatic cancer that has spread. About 900 participants will be randomly assigned to receive either the new combination or standard treatment. The goal is to see if the new combo shrinks tumors better and helps people live longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
China Medical University Hospital /ID# 279725
RECRUITINGTaichung, 40447, Taiwan
-
City Of Hope - Chicago /ID# 279814
RECRUITINGZion, Illinois, 60099, United States
-
Fiona Stanley Hospital /ID# 280079
NOT_YET_RECRUITINGMurdoch, Western Australia, 6150, Australia
-
Hadassah Medical Center-Hebrew University /ID# 279411
RECRUITINGJerusalem, 91120, Israel
-
Monash Health - Monash Medical Centre - Clayton /ID# 280076
NOT_YET_RECRUITINGClayton, Victoria, 3168, Australia
-
Prince Of Wales Hospital - Randwick /ID# 280085
NOT_YET_RECRUITINGRandwick, New South Wales, 2031, Australia
-
Rambam Health Care Campus- Haifa /ID# 279409
RECRUITINGHaifa, 3109601, Israel
-
Taipei Veterans General Hospital /ID# 279726
RECRUITINGTaipei, 112, Taiwan
-
Tamworth Hospital /ID# 280099
NOT_YET_RECRUITINGNorth Tamworth, New South Wales, 2340, Australia
-
Tel Aviv Sourasky Medical Center /ID# 279414
RECRUITINGTel Aviv, Tel Aviv, 6423906, Israel
-
Texas Oncology - Northeast Texas /ID# 280417
RECRUITINGTyler, Texas, 75702, United States
-
The Cancer Institute Hospital Of JFCR /ID# 280140
RECRUITINGKoto-ku, Tokyo, 135-8550, Japan
-
The Chaim Sheba Medical Center /ID# 279408
RECRUITINGRamat Gan, Tel Aviv, 5265601, Israel
-
Virginia Cancer Specialists - Fairfax /ID# 280415
RECRUITINGFairfax, Virginia, 22031, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
telisotuzumab adizutecan
What this could lead to
If successful, this could offer a new first-line treatment option for metastatic pancreatic cancer, potentially improving response rates and survival.
What could go wrong
This is an early-to-mid stage trial; the drug is investigational and may not prove better than standard care. Side effects from the combination therapy could be significant.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.